Physician profile
Khalid O Dar
NPI 1962414672
$1,336.85
in general payments reported to CMS, 2019-2025
12 companies · $315 in 2025
The $315 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16.06 · 2021: $205 · 2022: $271 · 2023: $184 · 2024: $345 · 2025: $315.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $845.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $844.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $459.56 | 2023-2025 | |
| Seagen INC. | $451.15 | 2021-2022 | |
| Janssen Biotech, INC. | $142.59 | 2022-2025 | Erleada, Talvey, Tecvayli |
| Lilly USA, LLC | $60.44 | 2024 | Omvoh |
| Merck Sharp & Dohme LLC | $54.06 | 2025 | Keytruda, Welireg, Keytruda Qlex |
| Pfizer INC. | $38.27 | 2024 | |
| Incyte Corporation | $29.55 | 2025 | Zynyz, Monjuvi |
| Abbvie INC. | $27.18 | 2025 | |
| Aveo Pharmaceuticals, INC. | $24.75 | 2025 | |
| Stemline Therapeutics INC. | $18.72 | 2025 | Orserdu |
| Janssen Pharmaceuticals, INC | $16.06 | 2019 | |
| Celgene Corporation | $14.52 | 2023 | Reblozyl |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khalid Dar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.